{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-003715","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.654766+00:00","generated_at":"2026-05-21T04:55:33.911692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial","bullets":["Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.","Net loss $1.8M for Q1 2025 vs $2.2M in Q1 2024; R&D expenses down 23% to $0.886M.","Phase 1b PH-762: 4 of 9 cSCC patients had pathologic complete response; no dose-limiting toxicities.","4th cohort enrolling; company expects to complete enrollment in Q3 2025.","Sufficient capital to complete treatment phase of Phase 1b trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-003715","json":"https://secwatch.observer/filing/0001683168-25-003715.json","markdown":"https://secwatch.observer/filing/0001683168-25-003715.md","text":"https://secwatch.observer/filing/0001683168-25-003715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/0001683168-25-003715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:55:33.911692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}